Insilico Medicine said results of a clinical trial in China showed positive results in treating idiopathic pulmonary fibrosis ...

Cimzia® is a registered trademark of UCB Pharma S.A.

Allegrow Biotech, Editact Therapeutics and Syngular Technology are finalists in the start-up pitch competition, 2025 EQT ...

The pending Nippon Steel deal would be unusual in granting the U.S. government some control over a private company—models ...

Windtree intends to accept cryptocurrency as an option for payment and also to hold as an assetWARRINGTON, Pa., June 03, 2025 (GLOBE NEWSWI ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer ...

There's no reason the U.S. can't pick up the pace to match the global clinical research front-runners without compromising ...

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a ...

Swiss biotechnology companies are stepping up expansion and investments in China, eyeing its huge market potential and improved policies to accommodate foreign capital, said executives and ...

Despite the slowdown in dealmaking, French drugmaker Sanofi on Monday agreed to buy immunology-focused biotech Blueprint Medicines in a deal worth up to $9.5bn and Bristol Myers Squibb struck an up to ...